News

A small Phase 1 clinical trial from the Georgetown University Medical Center (GUMC) suggests that the approved cancer drug Tasigna (nilotinib)can treat both motor and cognitive problems in patients with Parkinson’s disease or Lewy body dementia. The study, “Nilotinib Effects in Parkinson’s disease and Dementia with Lewy…

This week, a more than decade-old debate concerning the use of antipsychotic drugs in the elderly with dementia flared up after a study showing that these drugs also increased the risk of death in patients with Parkinson’s disease was published in the journal JAMA Neurology. Authored by Dr. Daniel…

While investigating links to Gaucher disease — a rare genetic condition with strong ties to Parkinson’s — researchers collaborating across three National Institutes of Health (NIH) centers reported finding a drug molecule potentially capable of treating Parkinson’s by reducing the clusters of aggregated α-synuclein inside cells. In doing so, the research…

Researchers at Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai in New York discovered that traumatic brain injury can often precede the development of Parkinson’s disease. The study “Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings,” published in …

Gene mutations are often associated with something negative, but analyzing data from ADAGIO — the largest Phase 3 clinical trial to date exploring the drug rasagiline (Azilect) in patients with early stage Parkinson’s disease — researchers identified two gene variants that determine a particularly good treatment response. Published in…

Parkinson’s disease patients in Europe will soon have to access a new treatment option for their disease, after the European Commission (EC) approved the use of  Ongentys (opicapone) — developed and marketed by Bial — as an adjunctive therapy for patients with motor fluctuation. The drug, a third-generation catechol-O-methyltransferase (COMT) inhibitor, is approved as…

A protein linked to the presence and severity of Parkinson’s has been found in urine samples from patients — opening the possibility that it can be developed into a biomarker, greatly aiding disease diagnosis and research. The finding, by researchers at the University of Alabama at Birmingham (UAB), led to two publications. In…

Sequencing the DNA of genes with known links to Parkinson’s disease revealed a previously unknown mutation in a patient with early onset disease, but while the evidence in the study pointed to the mutation as harmful, more research is needed to confirm that role. The study “Analysis of the…

Studies of the fruit fly, or Drosophila melanogaster, have shown that a protein called clueless, or clu, is associated with the mitochondrial defects observed in Parkinson’s disease patients. The study showing that clu mutations lead to muscle degeneration, “Drosophila clueless is involved in Parkin-dependent mitophagy by promoting VCP-mediated Marf…

Cynapsus Therapeutics has enrolled the final patient in its pivotal Phase 3 clinical study investigating the clinical effects of APL-130277, a fast-acting sublingual thin film for the treatment of debilitating OFF states in Parkinson’s disease (PD). Dose-titration phase results and a final evaluation of the study are expected to be released by the…